Spectral medical announces major milestone by reaching its interim enrollment target of 90 patients

Toronto, feb. 15, 2024 (globe newswire) -- spectral medical inc. (“spectral” or the “company”) (tsx: edt), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its interim enrollment target of patient 90 in its tigris trial.
BAX Ratings Summary
BAX Quant Ranking